Tune Therapeutics has reported early clinical evidence that its epigenetic silencing technology can durably suppress the hepatitis B virus (HBV) in humans by targeting the virus’s “molecular reservoir,” according to data presented at the European Association for the Study of Liver (EASL) Congress. By modulating gene expression without permanently editing DNA, the therapy, TUNE-401, aims to achieve a genetic-level effect that previous downstream antiviral treatments have failed to reach.
How Epigenetic Silencing Targets the HBV Reservoir
The primary challenge in treating chronic HBV is the presence of covalently closed circular DNA (cccDNA), a stable mini-chromosome that persists in liver cells and acts as a template for viral replication. According to John McHutchison, MD, CEO and chairman of Tune Therapeutics, previous industry efforts focused on “downstream” targets like RNA transcripts. While these drugs can reduce viral loads, they leave the cccDNA intact, causing the virus to return once treatment stops. Tune’s approach uses a methyltransferase enzyme and a chromatin-compacting protein module to silence the cccDNA directly. McHutchison notes that this process creates a “methylation fingerprint” that is inheritable through cell division, potentially offering a more durable, long-term solution than current standard-of-care antivirals.
Current antiviral treatments for HBV have been used for decades, but because they do not eliminate the cccDNA reservoir, they rarely result in a complete cure. Tune’s clinical data suggests that silencing this reservoir could change the trajectory of HBV management.
Comparing Functional Cures vs. Genetic Silencing
The distinction between a functional cure and a genetic cure remains a central point of debate in hepatology. GSK’s experimental drug bepirovirsen, an antisense oligonucleotide, has shown success in achieving functional cures—defined as the absence of detectable surface antigens for at least 24 weeks—in 19% of participants in Phase III trials, per company reports. McHutchison characterizes these functional cures as an immune-stimulating approach rather than a permanent genetic fix. While he acknowledges the value of bepirovirsen for patients, he argues that Tune’s epigenetic platform addresses the virus at its source, suggesting that the two approaches may ultimately serve different roles in future combination therapies.
What Does the Phase Ib/IIa Clinical Data Show?
In a small trial of 26 participants, Tune reported that TUNE-401 demonstrated deep and durable antiviral activity, with biomarker suppression observed in 100% of patients treated at mid-to-high dose levels. According to the company, some patients maintained suppressed viral markers for as long as 17 months after a single intravenous infusion. Safety data appears favorable thus far; McHutchison states that observed side effects, such as transient liver enzyme elevations and minor platelet reductions, are consistent with or better than those seen with other lipid nanoparticle (LNP) delivery systems. The company plans to initiate a larger Phase II study in late 2026 to further optimize dosing and test combination regimens.
Pro Tip: Understanding Viral Diversity
One hurdle for any HBV therapy is the genetic variability of the virus across different global populations. Tune estimates its current platform covers 98.5% of known HBV variants, though ongoing sequencing from their diverse patient cohort in New Zealand, Hong Kong, and Moldova will be necessary to confirm efficacy across all genotypes.
Frequently Asked Questions
How does Tune’s therapy differ from CRISPR gene editing?
Unlike CRISPR, which physically cuts or alters the DNA sequence, Tune’s epigenetic therapy uses a protein module to compact chromatin and silence gene expression without changing the underlying genetic code. This avoids the risks associated with permanent genomic modifications.
Is a single dose of TUNE-401 enough to cure HBV?
Early data shows that a single dose can produce a profound effect, but some participants in the study received multiple doses. Tune is currently evaluating whether a single infusion is sufficient or if a multidose regimen is required for long-term remission.
What are the next steps for Tune Therapeutics?
The company is focusing on dose optimization and plans to launch a larger Phase II trial by late 2026. They are also exploring the application of their epigenetic platform to other conditions, including cardiovascular disease and type 1 diabetes.
Are you interested in the future of genetic medicine? Subscribe to our weekly newsletter for the latest updates on clinical breakthroughs and biotechnology trends.
